Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
2 "Soonil Lee"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Multicenter Retrospective Analysis of Clinical Characteristics, Treatment Patterns, and Outcomes in Very Elderly Patients with Diffuse Large B-Cell Lymphoma: The Korean Cancer Study Group LY16-01
Jung Hye Choi, Tae Min Kim, Hyo Jung Kim, Sung Ae Koh, Yeung-Chul Mun, Hye Jin Kang, Yun Hwa Jung, Hyeok Shim, So Young Chong, Der-Sheng Sun, Soonil Lee, Byeong Bae Park, Jung Hye Kwon, Seung-Hyun Nam, Jun Ho Yi, Young Jin Yuh, Jong-Youl Jin, Jae Joon Han, Seok-Hyun Kim
Cancer Res Treat. 2018;50(2):590-598.   Published online June 9, 2017
DOI: https://doi.org/10.4143/crt.2017.172
AbstractAbstract PDFPubReaderePub
Purpose
The treatment strategy for elderly patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) has not been established because of poor treatment tolerability and lack of data.
Materials and Methods
This multicenter retrospective study was conducted to investigate clinical characteristics, treatment patterns and outcomes of patients older than 80 years who were diagnosed with DLBCL at 19 institutions in Korea between 2005 and 2016.
Results
A total of 194 patients were identified (median age, 83.3 years). Of these, 114 patients had an age-adjusted International Prognostic Index (aaIPI) score of 2-3 and 48 had a Charlson index score of 4 or more. R-CHOP was given in 124 cases, R-CVP in 13 cases, other chemotherapy in 17 cases, radiation alone in nine cases, and surgery alone in two cases. Twenty-nine patients did not undergo any treatment. The median number of chemotherapy cycles was three. Only 37 patients completed the planned treatment cycles. The overall response rate from 105 evaluable patientswas 90.5% (complete response, 41.9%). Twentynine patients died due to treatment-related toxicities (TRT). Thirteen patients died due to TRT after the first cycle. Median overall survival was 14.0 months. The main causes of death were disease progression (30.8%) and TRT (27.1%). In multivariate analysis, overall survival was affected by aaIPI, hypoalbuminemia, elevated creatinine, and treatment.
Conclusion
Age itself should not be a contraindication to treatment. However, since elderly patients show higher rates of TRT due to infection, careful monitoring and dose modification of chemotherapeutic agents is needed.

Citations

Citations to this article as recorded by  
  • Treatment Patterns and Costs Among US Patients With Diffuse Large B-Cell Lymphoma not Treated With 2L Stem Cell Transplantation
    Teofilia Acheampong, Tao Gu, Trong Kim Le, Scott J Keating
    Future Oncology.2024; 20(10): 623.     CrossRef
  • Identification of independent risk factors for hypoalbuminemia in patients with CKD stages 3 and 4: the construction of a nomogram
    Chong-Hui Wang, Meng-Han Jiang, Ji-Min Ma, Ming-Cong Yuan, Lei Liao, Hao-Zhang Duan, Dan Wang, Lian Duan
    Frontiers in Nutrition.2024;[Epub]     CrossRef
  • TRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma
    Will Harris, Edward J. Bataillard, Yoonha Choi, Tarec C. El-Galaly, Vaikunth Cuchelkar, Carsten Henneges, Antonia Kwan, Daniel J. Schneider, Joseph N. Paulson, Tina G. Nielsen
    JCO Clinical Cancer Informatics.2022;[Epub]     CrossRef
  • A Multicenter Study of 239 Patients Aged Over 70 Years With Diffuse Large B-Cell Lymphoma in China
    Chunli Yang, Qiaoer Li, Ke Xie, Yakun Zhang, Dania Xiang, Yunwei Han, Liqun Zou
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Cachexia index as a potential biomarker for cancer cachexia and a prognostic indicator in diffuse large B‐cell lymphoma
    Se‐Il Go, Mi Jung Park, Sungwoo Park, Myoung Hee Kang, Hoon‐Gu Kim, Jung Hun Kang, Jung Hoon Kim, Gyeong‐Won Lee
    Journal of Cachexia, Sarcopenia and Muscle.2021; 12(6): 2211.     CrossRef
  • Treatment approaches for older and oldest patients with diffuse large B-cell lymphoma – Use of non-R-CHOP alternative therapies and impact of comorbidities on treatment choices and outcome: A Humedica database retrospective cohort analysis, 2007–2015
    Vicki A. Morrison, Laurie Hamilton, Augustina Ogbonnaya, Aditya Raju, Kristin Hennenfent, Aaron Galaznik
    Journal of Geriatric Oncology.2020; 11(1): 41.     CrossRef
  • Clinical characteristics, treatment patterns and outcomes of patients older than 80 years diagnosed with DLBCL in China over a 10-year period
    Zhan Shi, Xi Tang, Qianwen Shen, Jiayan Chen, Fei Liu, Xi Chen, Jingwen Wang, Jie Zhuang
    Cancer Chemotherapy and Pharmacology.2019; 84(1): 127.     CrossRef
  • Antineoplastics

    Reactions Weekly.2018; 1701(1): 32.     CrossRef
  • 10,749 View
  • 320 Download
  • 8 Web of Science
  • 8 Crossref
Close layer
Current Status and Challenges of Cancer Clinical Trials in Korea
Byoung Yong Shim, Se Hoon Park, Soonil Lee, Jin-Soo Kim, Kyoung Eun Lee, Yoon-Koo Kang, Myung-Ju Ahn
Cancer Res Treat. 2016;48(1):20-27.   Published online March 2, 2015
DOI: https://doi.org/10.4143/crt.2014.317
AbstractAbstract PDFPubReaderePub
Purpose
Cancer clinical trials in Korea have rapidly progressed in terms of quantity and quality during the last decade. This study evaluates the current status of cancer clinical trials in Korea and their associated problems. Materials and Methods We analyzed the clinical trials approved by the Korea Food and Drug Administration (KFDA) between 2007 and 2013. A nationwide on-line survey containing 22 questions was also performed with several cooperative study groups and individual researchers in 56 academic hospitals.
Results
The number of cancer clinical trials approved by the KFDA increased almost twofold from 2007 to 2013. The number of sponsor-initiated clinical trials (SITs) increased by 50% and investigator-initiated clinical trials (IITs) increased by almost 640%. Three hundred and fortyfour clinical trials were approved by the KFDA between 2012 and 2013. At the time of the on-line survey (August 2013), 646 SITs and 519 IITs were ongoing in all hospitals. Six high volume hospitals were each conducting more than 50 clinical trials, including both SITs and IITs. Fifty-six investigators (31%) complained of the difficulties in raising funds to conduct clinical trials. Conclusion The number of cancer clinical trials in Korea rapidly increased from 2007 to 2013, as has the number of multicenter clinical trials and IITs run by cooperative study groups. Limited funding for IIT is a serious problem, and more financial support is needed both from government agencies and public donations from non-profit organizations.

Citations

Citations to this article as recorded by  
  • The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
    Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yu
    Cancer Research and Treatment.2025; 57(1): 39.     CrossRef
  • Trends of clinical trials from 2017 to 2019 in Korea: an integrated analysis based on the Ministry of Food and Drug Safety (MFDS) and the Clinical Research Information Service (CRIS) registries
    Ki Young Huh, Kyung-Sang Yu, Hyeong-Seok Lim, Hyungsub Kim
    Translational and Clinical Pharmacology.2021; 29(4): 186.     CrossRef
  • Regional Differences in Access to Clinical Trials for Cancer in Korea
    Woorim Kim, Seongkyeong Jang, Yoon Jung Chang
    Quality Improvement in Health Care.2021; 27(1): 20.     CrossRef
  • Effects of pharmacist interventions on reducing prescribing errors of investigational drugs in oncology clinical trials
    Jin Young Moon, Yeonhong Lee, Ji Min Han, Mi Hyung Lee, Jeong Yee, Mi Kyung Song, Young Ju Kim, Hye Sun Gwak
    Journal of Oncology Pharmacy Practice.2020; 26(1): 29.     CrossRef
  • Anticancer Agents Based on Vulnerable Components in a Signalling Pathway
    Ankur Vaidya, Shweta Jain, Sanjeev Sahu, Pankaj Kumar Jain, Kamla Pathak, Devender Pathak, Raj Kumar, Sanjay Kumar Jain
    Mini-Reviews in Medicinal Chemistry.2020; 20(10): 886.     CrossRef
  • Linguistic Validation of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Korean
    Juhee Cho, Junghee Yoon, Youngha Kim, Dongryul Oh, Seok Jin Kim, Jinseok Ahn, Gee Young Suh, Seok Jin Nam, Sandra A. Mitchell
    Journal of Global Oncology.2019; (5): 1.     CrossRef
  • Survey of Medical Oncology Status in Korea (SOMOS-K): A National Survey of Medical Oncologists in the Korean Association for Clinical Oncology (KACO)
    Do Yeun Kim, Yun Gyoo Lee, Bong-Seog Kim
    Cancer Research and Treatment.2017; 49(3): 588.     CrossRef
  • Korean Cancer Patients’ Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate
    Yoojoo Lim, Jee Min Lim, Won Jae Jeong, Kyung-Hun Lee, Bhumsuk Keam, Tae-Yong Kim, Tae Min Kim, Sae-Won Han, Do Youn Oh, Dong-Wan Kim, Tae-You Kim, Dae Seog Heo, Yung-Jue Bang, Seock-Ah Im
    Cancer Research and Treatment.2017; 49(4): 1033.     CrossRef
  • 11,377 View
  • 129 Download
  • 8 Web of Science
  • 8 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP